Global Urological Cancer Drugs Market Research Report 2023

Report ID: 1912285 | Published Date: Jan 2025 | No. of Page: 101 | Base Year: 2024 | Rating: 4.2 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Urological Cancer Drugs Market Overview
    1.1 Product Overview and Scope of Urological Cancer Drugs
    1.2 Urological Cancer Drugs Segment by Type
        1.2.1 Global Urological Cancer Drugs Sales Growth Rate Comparison by Type (2022-2028)
        1.2.2 Tablets
        1.2.3 Injection
    1.3 Urological Cancer Drugs Segment by Application
        1.3.1 Global Urological Cancer Drugs Sales Comparison by Application: (2022-2028)
        1.3.2 Prostate Cancer
        1.3.3 Bladder Cancer
        1.3.4 Kidney Cancer
        1.3.5 Testicular Cancer
        1.3.6 Others
    1.4 Global Urological Cancer Drugs Market Size Estimates and Forecasts
        1.4.1 Global Urological Cancer Drugs Revenue 2017-2028
        1.4.2 Global Urological Cancer Drugs Sales 2017-2028
        1.4.3 Urological Cancer Drugs Market Size by Region: 2017 Versus 2021 Versus 2028
2 Urological Cancer Drugs Market Competition by Manufacturers
    2.1 Global Urological Cancer Drugs Sales Market Share by Manufacturers (2017-2022)
    2.2 Global Urological Cancer Drugs Revenue Market Share by Manufacturers (2017-2022)
    2.3 Global Urological Cancer Drugs Average Price by Manufacturers (2017-2022)
    2.4 Manufacturers Urological Cancer Drugs Manufacturing Sites, Area Served, Product Type
    2.5 Urological Cancer Drugs Market Competitive Situation and Trends
        2.5.1 Urological Cancer Drugs Market Concentration Rate
        2.5.2 The Global Top 5 and Top 10 Largest Urological Cancer Drugs Players Market Share by Revenue
        2.5.3 Global Urological Cancer Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Urological Cancer Drugs Retrospective Market Scenario by Region
    3.1 Global Urological Cancer Drugs Retrospective Market Scenario in Sales by Region: 2017-2022
    3.2 Global Urological Cancer Drugs Retrospective Market Scenario in Revenue by Region: 2017-2022
    3.3 North America Urological Cancer Drugs Market Facts & Figures by Country
        3.3.1 North America Urological Cancer Drugs Sales by Country
        3.3.2 North America Urological Cancer Drugs Revenue by Country
        3.3.3 U.S.
        3.3.4 Canada
    3.4 Europe Urological Cancer Drugs Market Facts & Figures by Country
        3.4.1 Europe Urological Cancer Drugs Sales by Country
        3.4.2 Europe Urological Cancer Drugs Revenue by Country
        3.4.3 Germany
        3.4.4 France
        3.4.5 U.K.
        3.4.6 Italy
        3.4.7 Russia
    3.5 Asia Pacific Urological Cancer Drugs Market Facts & Figures by Region
        3.5.1 Asia Pacific Urological Cancer Drugs Sales by Region
        3.5.2 Asia Pacific Urological Cancer Drugs Revenue by Region
        3.5.3 China
        3.5.4 Japan
        3.5.5 South Korea
        3.5.6 India
        3.5.7 Australia
        3.5.8 Taiwan
        3.5.9 Indonesia
        3.5.10 Thailand
        3.5.11 Malaysia
        3.5.12 Philippines
        3.5.13 Vietnam
    3.6 Latin America Urological Cancer Drugs Market Facts & Figures by Country
        3.6.1 Latin America Urological Cancer Drugs Sales by Country
        3.6.2 Latin America Urological Cancer Drugs Revenue by Country
        3.6.3 Mexico
        3.6.4 Brazil
        3.6.5 Argentina
    3.7 Middle East and Africa Urological Cancer Drugs Market Facts & Figures by Country
        3.7.1 Middle East and Africa Urological Cancer Drugs Sales by Country
        3.7.2 Middle East and Africa Urological Cancer Drugs Revenue by Country
        3.7.3 Turkey
        3.7.4 Saudi Arabia
        3.7.5 U.A.E
4 Global Urological Cancer Drugs Historic Market Analysis by Type
    4.1 Global Urological Cancer Drugs Sales Market Share by Type (2017-2022)
    4.2 Global Urological Cancer Drugs Revenue Market Share by Type (2017-2022)
    4.3 Global Urological Cancer Drugs Price by Type (2017-2022)
5 Global Urological Cancer Drugs Historic Market Analysis by Application
    5.1 Global Urological Cancer Drugs Sales Market Share by Application (2017-2022)
    5.2 Global Urological Cancer Drugs Revenue Market Share by Application (2017-2022)
    5.3 Global Urological Cancer Drugs Price by Application (2017-2022)
6 Key Companies Profiled
    6.1 Novartis
        6.1.1 Novartis Corporation Information
        6.1.2 Novartis Description and Business Overview
        6.1.3 Novartis Urological Cancer Drugs Sales, Revenue and Gross Margin (2017-2022)
        6.1.4 Novartis Urological Cancer Drugs Product Portfolio
        6.1.5 Novartis Recent Developments/Updates
    6.2 Pfizer
        6.2.1 Pfizer Corporation Information
        6.2.2 Pfizer Description and Business Overview
        6.2.3 Pfizer Urological Cancer Drugs Sales, Revenue and Gross Margin (2017-2022)
        6.2.4 Pfizer Urological Cancer Drugs Product Portfolio
        6.2.5 Pfizer Recent Developments/Updates
    6.3 Johnson & Johnson
        6.3.1 Johnson & Johnson Corporation Information
        6.3.2 Johnson & Johnson Description and Business Overview
        6.3.3 Johnson & Johnson Urological Cancer Drugs Sales, Revenue and Gross Margin (2017-2022)
        6.3.4 Johnson & Johnson Urological Cancer Drugs Product Portfolio
        6.3.5 Johnson & Johnson Recent Developments/Updates
    6.4 AstraZeneca
        6.4.1 AstraZeneca Corporation Information
        6.4.2 AstraZeneca Description and Business Overview
        6.4.3 AstraZeneca Urological Cancer Drugs Sales, Revenue and Gross Margin (2017-2022)
        6.4.4 AstraZeneca Urological Cancer Drugs Product Portfolio
        6.4.5 AstraZeneca Recent Developments/Updates
    6.5 Astellas
        6.5.1 Astellas Corporation Information
        6.5.2 Astellas Description and Business Overview
        6.5.3 Astellas Urological Cancer Drugs Sales, Revenue and Gross Margin (2017-2022)
        6.5.4 Astellas Urological Cancer Drugs Product Portfolio
        6.5.5 Astellas Recent Developments/Updates
    6.6 Bristol-Myers Squibb
        6.6.1 Bristol-Myers Squibb Corporation Information
        6.6.2 Bristol-Myers Squibb Description and Business Overview
        6.6.3 Bristol-Myers Squibb Urological Cancer Drugs Sales, Revenue and Gross Margin (2017-2022)
        6.6.4 Bristol-Myers Squibb Urological Cancer Drugs Product Portfolio
        6.6.5 Bristol-Myers Squibb Recent Developments/Updates
    6.7 Abbott Laboratories
        6.6.1 Abbott Laboratories Corporation Information
        6.6.2 Abbott Laboratories Description and Business Overview
        6.6.3 Abbott Laboratories Urological Cancer Drugs Sales, Revenue and Gross Margin (2017-2022)
        6.4.4 Abbott Laboratories Urological Cancer Drugs Product Portfolio
        6.7.5 Abbott Laboratories Recent Developments/Updates
    6.8 Celgene Corporation
        6.8.1 Celgene Corporation Corporation Information
        6.8.2 Celgene Corporation Description and Business Overview
        6.8.3 Celgene Corporation Urological Cancer Drugs Sales, Revenue and Gross Margin (2017-2022)
        6.8.4 Celgene Corporation Urological Cancer Drugs Product Portfolio
        6.8.5 Celgene Corporation Recent Developments/Updates
    6.9 Dendreon Corporation
        6.9.1 Dendreon Corporation Corporation Information
        6.9.2 Dendreon Corporation Description and Business Overview
        6.9.3 Dendreon Corporation Urological Cancer Drugs Sales, Revenue and Gross Margin (2017-2022)
        6.9.4 Dendreon Corporation Urological Cancer Drugs Product Portfolio
        6.9.5 Dendreon Corporation Recent Developments/Updates
    6.10 Ferring Pharmaceuticals
        6.10.1 Ferring Pharmaceuticals Corporation Information
        6.10.2 Ferring Pharmaceuticals Description and Business Overview
        6.10.3 Ferring Pharmaceuticals Urological Cancer Drugs Sales, Revenue and Gross Margin (2017-2022)
        6.10.4 Ferring Pharmaceuticals Urological Cancer Drugs Product Portfolio
        6.10.5 Ferring Pharmaceuticals Recent Developments/Updates
    6.11 GlaxoSmithKline
        6.11.1 GlaxoSmithKline Corporation Information
        6.11.2 GlaxoSmithKline Urological Cancer Drugs Description and Business Overview
        6.11.3 GlaxoSmithKline Urological Cancer Drugs Sales, Revenue and Gross Margin (2017-2022)
        6.11.4 GlaxoSmithKline Urological Cancer Drugs Product Portfolio
        6.11.5 GlaxoSmithKline Recent Developments/Updates
    6.12 Indevus Pharmaceuticals Inc
        6.12.1 Indevus Pharmaceuticals Inc Corporation Information
        6.12.2 Indevus Pharmaceuticals Inc Urological Cancer Drugs Description and Business Overview
        6.12.3 Indevus Pharmaceuticals Inc Urological Cancer Drugs Sales, Revenue and Gross Margin (2017-2022)
        6.12.4 Indevus Pharmaceuticals Inc Urological Cancer Drugs Product Portfolio
        6.12.5 Indevus Pharmaceuticals Inc Recent Developments/Updates
    6.13 Ipsen
        6.13.1 Ipsen Corporation Information
        6.13.2 Ipsen Urological Cancer Drugs Description and Business Overview
        6.13.3 Ipsen Urological Cancer Drugs Sales, Revenue and Gross Margin (2017-2022)
        6.13.4 Ipsen Urological Cancer Drugs Product Portfolio
        6.13.5 Ipsen Recent Developments/Updates
    6.14 Roche Healthcare
        6.14.1 Roche Healthcare Corporation Information
        6.14.2 Roche Healthcare Urological Cancer Drugs Description and Business Overview
        6.14.3 Roche Healthcare Urological Cancer Drugs Sales, Revenue and Gross Margin (2017-2022)
        6.14.4 Roche Healthcare Urological Cancer Drugs Product Portfolio
        6.14.5 Roche Healthcare Recent Developments/Updates
    6.15 Sanofi S.A
        6.15.1 Sanofi S.A Corporation Information
        6.15.2 Sanofi S.A Urological Cancer Drugs Description and Business Overview
        6.15.3 Sanofi S.A Urological Cancer Drugs Sales, Revenue and Gross Margin (2017-2022)
        6.15.4 Sanofi S.A Urological Cancer Drugs Product Portfolio
        6.15.5 Sanofi S.A Recent Developments/Updates
    6.16 Tolmar Inc
        6.16.1 Tolmar Inc Corporation Information
        6.16.2 Tolmar Inc Urological Cancer Drugs Description and Business Overview
        6.16.3 Tolmar Inc Urological Cancer Drugs Sales, Revenue and Gross Margin (2017-2022)
        6.16.4 Tolmar Inc Urological Cancer Drugs Product Portfolio
        6.16.5 Tolmar Inc Recent Developments/Updates
7 Urological Cancer Drugs Manufacturing Cost Analysis
    7.1 Urological Cancer Drugs Key Raw Materials Analysis
       7.1.1 Key Raw Materials
       7.1.2 Key Suppliers of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
    7.3 Manufacturing Process Analysis of Urological Cancer Drugs
    7.4 Urological Cancer Drugs Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
    8.1 Marketing Channel
    8.2 Urological Cancer Drugs Distributors List
    8.3 Urological Cancer Drugs Customers
9 Urological Cancer Drugs Market Dynamics
    9.1 Urological Cancer Drugs Industry Trends
    9.2 Urological Cancer Drugs Market Drivers
    9.3 Urological Cancer Drugs Market Challenges
    9.4 Urological Cancer Drugs Market Restraints
10 Global Market Forecast
    10.1 Urological Cancer Drugs Market Estimates and Projections by Type
        10.1.1 Global Forecasted Sales of Urological Cancer Drugs by Type (2023-2028)
        10.1.2 Global Forecasted Revenue of Urological Cancer Drugs by Type (2023-2028)
    10.2 Urological Cancer Drugs Market Estimates and Projections by Application
        10.2.1 Global Forecasted Sales of Urological Cancer Drugs by Application (2023-2028)
        10.2.2 Global Forecasted Revenue of Urological Cancer Drugs by Application (2023-2028)
    10.3 Urological Cancer Drugs Market Estimates and Projections by Region
        10.3.1 Global Forecasted Sales of Urological Cancer Drugs by Region (2023-2028)
        10.3.2 Global Forecasted Revenue of Urological Cancer Drugs by Region (2023-2028)
11 Research Finding and Conclusion
12 Methodology and Data Source
    12.1 Methodology/Research Approach
        12.1.1 Research Programs/Design
        12.1.2 Market Size Estimation
        12.1.3 Market Breakdown and Data Triangulation
    12.2 Data Source
        12.2.1 Secondary Sources
        12.2.2 Primary Sources
    12.3 Author List
    12.4 Disclaimer

List of Tables
    Table 1. Global Urological Cancer Drugs Sales Growth Rate Comparison by Type (2022-2028) & (K Pcs) & (US$ Million)
    Table 2. Global Urological Cancer Drugs Sales Growth Rate Comparison by Application (2022-2028) & (K Pcs) & (US$ Million)
    Table 3. Global Urological Cancer Drugs Market Size by Region (US$ Million) (2017 VS 2021 VS 2028)
    Table 4. Global Urological Cancer Drugs Market Competitive Situation by Manufacturers in 2021
    Table 5. Global Urological Cancer Drugs Sales (K Pcs) of Key Manufacturers (2017-2022)
    Table 6. Global Urological Cancer Drugs Sales Market Share by Manufacturers (2017-2022)
    Table 7. Global Urological Cancer Drugs Revenue (US$ Million) by Manufacturers (2017-2022)
    Table 8. Global Urological Cancer Drugs Revenue Share by Manufacturers (2017-2022)
    Table 9. Global Market Urological Cancer Drugs Average Price (USD/Pcs) of Key Manufacturers (2017-2022)
    Table 10. Manufacturers Urological Cancer Drugs Manufacturing Sites and Area Served
    Table 11. Manufacturers Urological Cancer Drugs Product Type
    Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 13. Global Urological Cancer Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Urological Cancer Drugs as of 2021)
    Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
    Table 15. Global Urological Cancer Drugs Sales by Region (2017-2022) & (K Pcs)
    Table 16. Global Urological Cancer Drugs Sales Market Share by Region (2017-2022)
    Table 17. Global Urological Cancer Drugs Revenue by Region (2017-2022) & (US$ Million)
    Table 18. Global Urological Cancer Drugs Revenue Market Share by Region (2017-2022)
    Table 19. North America Urological Cancer Drugs Sales by Country (2017-2022) & (K Pcs)
    Table 20. North America Urological Cancer Drugs Sales Market Share by Country (2017-2022)
    Table 21. North America Urological Cancer Drugs Revenue by Country (2017-2022) & (US$ Million)
    Table 22. North America Urological Cancer Drugs Revenue Market Share by Country (2017-2022)
    Table 23. Europe Urological Cancer Drugs Sales by Country (2017-2022) & (K Pcs)
    Table 24. Europe Urological Cancer Drugs Sales Market Share by Country (2017-2022)
    Table 25. Europe Urological Cancer Drugs Revenue by Country (2017-2022) & (US$ Million)
    Table 26. Europe Urological Cancer Drugs Revenue Market Share by Country (2017-2022)
    Table 27. Asia Pacific Urological Cancer Drugs Sales by Region (2017-2022) & (K Pcs)
    Table 28. Asia Pacific Urological Cancer Drugs Sales Market Share by Region (2017-2022)
    Table 29. Asia Pacific Urological Cancer Drugs Revenue by Region (2017-2022) & (US$ Million)
    Table 30. Asia Pacific Urological Cancer Drugs Revenue Market Share by Region (2017-2022)
    Table 31. Latin America Urological Cancer Drugs Sales by Country (2017-2022) & (K Pcs)
    Table 32. Latin America Urological Cancer Drugs Sales Market Share by Country (2017-2022)
    Table 33. Latin America Urological Cancer Drugs Revenue by Country (2017-2022) & (US$ Million)
    Table 34. Latin America Urological Cancer Drugs Revenue Market Share by Country (2017-2022)
    Table 35. Middle East and Africa Urological Cancer Drugs Sales by Country (2017-2022) & (K Pcs)
    Table 36. Middle East and Africa Urological Cancer Drugs Sales Market Share by Country (2017-2022)
    Table 37. Middle East and Africa Urological Cancer Drugs Revenue by Country (2017-2022) & (US$ Million)
    Table 38. Middle East and Africa Urological Cancer Drugs Revenue Market Share by Country (2017-2022)
    Table 39. Global Urological Cancer Drugs Sales by Type (2017-2022) & (K Pcs)
    Table 40. Global Urological Cancer Drugs Sales Market Share by Type (2017-2022)
    Table 41. Global Urological Cancer Drugs Revenue by Type (2017-2022) & (US$ Million)
    Table 42. Global Urological Cancer Drugs Revenue Share by Type (2017-2022)
    Table 43. Global Urological Cancer Drugs Price by Type (2017-2022) & (USD/Pcs)
    Table 44. Global Urological Cancer Drugs Sales (K Pcs) by Application (2017-2022)
    Table 45. Global Urological Cancer Drugs Sales Market Share by Application (2017-2022)
    Table 46. Global Urological Cancer Drugs Revenue by Application (2017-2022) & (US$ Million)
    Table 47. Global Urological Cancer Drugs Revenue Share by Application (2017-2022)
    Table 48. Global Urological Cancer Drugs Price by Application (2017-2022) & (USD/Pcs)
    Table 49. Novartis Corporation Information
    Table 50. Novartis Description and Business Overview
    Table 51. Novartis Urological Cancer Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 52. Novartis Urological Cancer Drugs Product
    Table 53. Novartis Recent Developments/Updates
    Table 54. Pfizer Corporation Information
    Table 55. Pfizer Description and Business Overview
    Table 56. Pfizer Urological Cancer Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 57. Pfizer Urological Cancer Drugs Product
    Table 58. Pfizer Recent Developments/Updates
    Table 59. Johnson & Johnson Corporation Information
    Table 60. Johnson & Johnson Description and Business Overview
    Table 61. Johnson & Johnson Urological Cancer Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 62. Johnson & Johnson Urological Cancer Drugs Product
    Table 63. Johnson & Johnson Recent Developments/Updates
    Table 64. AstraZeneca Corporation Information
    Table 65. AstraZeneca Description and Business Overview
    Table 66. AstraZeneca Urological Cancer Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 67. AstraZeneca Urological Cancer Drugs Product
    Table 68. AstraZeneca Recent Developments/Updates
    Table 69. Astellas Corporation Information
    Table 70. Astellas Description and Business Overview
    Table 71. Astellas Urological Cancer Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 72. Astellas Urological Cancer Drugs Product
    Table 73. Astellas Recent Developments/Updates
    Table 74. Bristol-Myers Squibb Corporation Information
    Table 75. Bristol-Myers Squibb Description and Business Overview
    Table 76. Bristol-Myers Squibb Urological Cancer Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 77. Bristol-Myers Squibb Urological Cancer Drugs Product
    Table 78. Bristol-Myers Squibb Recent Developments/Updates
    Table 79. Abbott Laboratories Corporation Information
    Table 80. Abbott Laboratories Description and Business Overview
    Table 81. Abbott Laboratories Urological Cancer Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 82. Abbott Laboratories Urological Cancer Drugs Product
    Table 83. Abbott Laboratories Recent Developments/Updates
    Table 84. Celgene Corporation Corporation Information
    Table 85. Celgene Corporation Description and Business Overview
    Table 86. Celgene Corporation Urological Cancer Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 87. Celgene Corporation Urological Cancer Drugs Product
    Table 88. Celgene Corporation Recent Developments/Updates
    Table 89. Dendreon Corporation Corporation Information
    Table 90. Dendreon Corporation Description and Business Overview
    Table 91. Dendreon Corporation Urological Cancer Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 92. Dendreon Corporation Urological Cancer Drugs Product
    Table 93. Dendreon Corporation Recent Developments/Updates
    Table 94. Ferring Pharmaceuticals Corporation Information
    Table 95. Ferring Pharmaceuticals Description and Business Overview
    Table 96. Ferring Pharmaceuticals Urological Cancer Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 97. Ferring Pharmaceuticals Urological Cancer Drugs Product
    Table 98. Ferring Pharmaceuticals Recent Developments/Updates
    Table 99. GlaxoSmithKline Corporation Information
    Table 100. GlaxoSmithKline Description and Business Overview
    Table 101. GlaxoSmithKline Urological Cancer Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 102. GlaxoSmithKline Urological Cancer Drugs Product
    Table 103. GlaxoSmithKline Recent Developments/Updates
    Table 104. Indevus Pharmaceuticals Inc Corporation Information
    Table 105. Indevus Pharmaceuticals Inc Description and Business Overview
    Table 106. Indevus Pharmaceuticals Inc Urological Cancer Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 107. Indevus Pharmaceuticals Inc Urological Cancer Drugs Product
    Table 108. Indevus Pharmaceuticals Inc Recent Developments/Updates
    Table 109. Ipsen Corporation Information
    Table 110. Ipsen Description and Business Overview
    Table 111. Ipsen Urological Cancer Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 112. Ipsen Urological Cancer Drugs Product
    Table 113. Ipsen Recent Developments/Updates
    Table 114. Roche Healthcare Corporation Information
    Table 115. Roche Healthcare Description and Business Overview
    Table 116. Roche Healthcare Urological Cancer Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 117. Roche Healthcare Urological Cancer Drugs Product
    Table 118. Roche Healthcare Recent Developments/Updates
    Table 119. Sanofi S.A Corporation Information
    Table 120. Sanofi S.A Description and Business Overview
    Table 121. Sanofi S.A Urological Cancer Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 122. Sanofi S.A Urological Cancer Drugs Product
    Table 123. Sanofi S.A Recent Developments/Updates
    Table 124. Tolmar Inc Corporation Information
    Table 125. Tolmar Inc Description and Business Overview
    Table 126. Tolmar Inc Urological Cancer Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 127. Tolmar Inc Urological Cancer Drugs Product
    Table 128. Tolmar Inc Recent Developments/Updates
    Table 129. Production Base and Market Concentration Rate of Raw Material
    Table 130. Key Suppliers of Raw Materials
    Table 131. Urological Cancer Drugs Distributors List
    Table 132. Urological Cancer Drugs Customers List
    Table 133. Urological Cancer Drugs Market Trends
    Table 134. Urological Cancer Drugs Market Drivers
    Table 135. Urological Cancer Drugs Market Challenges
    Table 136. Urological Cancer Drugs Market Restraints
    Table 137. Global Urological Cancer Drugs Sales Forecast by Type (2023-2028) & (K Pcs)
    Table 138. Global Urological Cancer Drugs Sales Market Share Forecast by Type (2023-2028)
    Table 139. Global Urological Cancer Drugs Revenue Forecast by Type (2023-2028) & (US$ Million)
    Table 140. Global Urological Cancer Drugs Revenue Market Share Forecast by Type (2023-2028)
    Table 141. Global Urological Cancer Drugs Sales Forecast by Application (2023-2028) & (K Pcs)
    Table 142. Global Urological Cancer Drugs Sales Market Share Forecast by Application (2023-2028)
    Table 143. Global Urological Cancer Drugs Revenue Forecast by Application (2023-2028) & (US$ Million)
    Table 144. Global Urological Cancer Drugs Revenue Market Share Forecast by Application (2023-2028)
    Table 145. Global Urological Cancer Drugs Sales Forecast by Region (2023-2028) & (K Pcs)
    Table 146. Global Urological Cancer Drugs Sales Market Share Forecast by Region (2023-2028)
    Table 147. Global Urological Cancer Drugs Revenue Forecast by Region (2023-2028) & (US$ Million)
    Table 148. Global Urological Cancer Drugs Revenue Market Share Forecast by Region (2023-2028)
    Table 149. Research Programs/Design for This Report
    Table 150. Key Data Information from Secondary Sources
    Table 151. Key Data Information from Primary Sources
List of Figures
    Figure 1. Product Picture of Urological Cancer Drugs
    Figure 2. Global Urological Cancer Drugs Market Share by Type in 2021 & 2028
    Figure 3. Tablets Product Picture
    Figure 4. Injection Product Picture
    Figure 5. Global Urological Cancer Drugs Market Share by Application in 2021 & 2028
    Figure 6. Prostate Cancer
    Figure 7. Bladder Cancer
    Figure 8. Kidney Cancer
    Figure 9. Testicular Cancer
    Figure 10. Others
    Figure 11. Global Urological Cancer Drugs Revenue, (US$ Million), 2017 VS 2021 VS 2028
    Figure 12. Global Urological Cancer Drugs Market Size (2017-2028) & (US$ Million)
    Figure 13. Global Urological Cancer Drugs Sales (2017-2028) & (K Pcs)
    Figure 14. Urological Cancer Drugs Sales Share by Manufacturers in 2021
    Figure 15. Global Urological Cancer Drugs Revenue Share by Manufacturers in 2021
    Figure 16. The Global 5 and 10 Largest Urological Cancer Drugs Players: Market Share by Revenue in 2021
    Figure 17. Urological Cancer Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2017 VS 2021
    Figure 18. Global Urological Cancer Drugs Sales Market Share by Region (2017-2022)
    Figure 19. Global Urological Cancer Drugs Sales Market Share by Region in 2021
    Figure 20. Global Urological Cancer Drugs Revenue Market Share by Region (2017-2022)
    Figure 21. Global Urological Cancer Drugs Revenue Market Share by Region in 2021
    Figure 22. U.S. Urological Cancer Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 23. Canada Urological Cancer Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 24. Germany Urological Cancer Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 25. France Urological Cancer Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 26. U.K. Urological Cancer Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 27. Italy Urological Cancer Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 28. Russia Urological Cancer Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 29. China Urological Cancer Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 30. Japan Urological Cancer Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 31. South Korea Urological Cancer Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 32. India Urological Cancer Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 33. Australia Urological Cancer Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 34. Taiwan Urological Cancer Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 35. Indonesia Urological Cancer Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 36. Thailand Urological Cancer Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 37. Malaysia Urological Cancer Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 38. Philippines Urological Cancer Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 39. Vietnam Urological Cancer Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 40. Mexico Urological Cancer Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 41. Brazil Urological Cancer Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 42. Argentina Urological Cancer Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 43. Turkey Urological Cancer Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 44. Saudi Arabia Urological Cancer Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 45. U.A.E Urological Cancer Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 46. Sales Market Share of Urological Cancer Drugs by Type (2017-2022)
    Figure 47. Manufacturing Cost Structure of Urological Cancer Drugs
    Figure 48. Manufacturing Process Analysis of Urological Cancer Drugs
    Figure 49. Urological Cancer Drugs Industrial Chain Analysis
    Figure 50. Channels of Distribution
    Figure 51. Distributors Profiles
    Figure 52. Bottom-up and Top-down Approaches for This Report
    Figure 53. Data Triangulation
    Figure 54. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Novartis
Pfizer
Johnson & Johnson
AstraZeneca
Astellas
Bristol-Myers Squibb
Abbott Laboratories
Celgene Corporation
Dendreon Corporation
Ferring Pharmaceuticals
GlaxoSmithKline
Indevus Pharmaceuticals Inc
Ipsen
Roche Healthcare
Sanofi S.A
Tolmar Inc
Frequently Asked Questions
Urological Cancer Drugs report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Urological Cancer Drugs report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Urological Cancer Drugs report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports